Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629557 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
A Phase 4 study, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT07629557 is a Phase 4 study that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 15 participants.
The verdict
NCT07629557, a Phase 4 study, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
Interventions
- DRUG Riboflavin Ophthalmic Solutions
- DEVICE UV-A Irradiation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07629557
The ClinicalTrials.gov registry entry for NCT07629557 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riboflavin Ophthalmic Solutions is the first listed.
NCT07629557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07629557 about?
NCT07629557 is a clinical study titled "Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus". Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
What is the current status of trial NCT07629557?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2026-05-11. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07629557?
The interventions under investigation include: Riboflavin Ophthalmic Solutions (DRUG), UV-A Irradiation System (DEVICE).
Who is sponsoring clinical trial NCT07629557?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.